Navigation Links
GlySure Wins 2013 Small Business of the Year and New Product of the Year

OXFORD, England, October 1, 2013 /PRNewswire/ --

GlySure Limited, developer of in-hospital continuous blood glucose monitoring (CBGM) systems, today announced that it has won two major awards in the 2013 BIG (Business Intelligence Group) Awards for Business.

BIG has selected GlySure as Small Business of the Year and it also won New Product of the Year for its CBGM technology.

Business Intelligence Group's BIG Awards specialize in recognizing top performing companies and organizations. The organization's proprietary and unique scoring system selectively measures performance across multiple business domains, and rewards companies whose achievements stand above those of their peers.

"Glysure's mission and product to help control glucose levels in real time is clearly in demand," said Dawn Fordyce of the Business Intelligence Group. "With so much at stake, Glysure's continuous blood glucose monitoring system will surely save countless lives and healthcare costs."

Over two years of human use trials in over 150 intensive care unit (ICU) patients have proven that GlySure's CBGM technology can be used to continuously measure glucose levels with an extremely high degree of accuracy and repeatability across three-to-five days of a patient's stay, which is key to improving outcomes and reducing costs in the ICU. GlySure recently commenced a multi-center CE Trial on cardiac surgery patients, which the company expects to complete this fall.

"It is a great honor to be recognized by the Business Intelligence Group," said GlySure CEO Chris Jones. "This industry recognition validates the tremendous momentum we've achieved to date in delivering on the promise of Tight Glycemic Control."

About GlySure:

GlySure has developed a continuous intravascular glucose monitoring system using a proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU).  The company has demonstrated through ICU testing highly accurate sensors which can provide continuous glucose readings throughout the length of a patient's stay in the ICU. GlySure was founded in 2006, it is based in Abingdon, Oxfordshire, England and it has 30 employees. The company's products are not approved for use in the U.S. or Europe.

Company Contact: Chris Jones, CEO, GlySure. Tel: +44(0)1235-462-870.

Media Contact: Kara Della Vecchia, KDV Communications, Inc. Tel: +1-508-314-3127.

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Glysure Appoints Justine McQuillan as European Director of Clinical Affairs
2. Study Demonstrates Glysure Systems Ability to Accurately Measure Blood Glucose Levels in the ICU
3. GlySure CEO to Present ICU Trial Results at Spring Medtech Industry Conferences
4. GlySure Earns ISO 13485 Certification
5. MabVax Therapeutics Receives $1,750,000 Small Business Innovation Research Contract Award From The National Cancer Institute To Support Development of Novel Pancreatic Cancer Diagnostic Imaging Agent
6. GlaxoSmithKline, Community Care of North Carolina harness "small data" to improve patient care and reduce health care costs
7. PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022
8. PDL BioPharma to Present at the 4th Annual Credit Suisse Small/Mid Cap Conference
9. Arisaph Pharmaceuticals Awarded Phase I STTR Grant To Develop Small Molecule Immune Modulators
10. Alzheimers Drug Discovery Foundation Supports Madera Biosciences to Advance Small Molecule Drugs that Upregulate apoE
11. Structure-Based Drug Design Conference in Boston, Starting June 19 PLUS These 62 Start-ups and Small Companies Will Transform Drug Delivery Technology
Post Your Comments:
(Date:10/13/2015)... 2015 Health Gorilla ( ) today announced ... – a secure platform for clinical data and communications poised ... and manage healthcare in the US. The launch follows the ... combined total of $4.4M raised to date, with Data ... Ventures , Harris Barton , Orfin Ventures ...
(Date:10/13/2015)... , October 13, 2015 --> ... ,What can be expected from the Asthma and COPD Therapies ... rates? Visiongain ,s brand new report shows you potential ... ,  ,Our 309-page report provides 260 tables, charts, and graphs. ... future market prospects. Our new study lets you assess forecasted ...
(Date:10/13/2015)... SPRINGS, N.C. , Oct. 13, 2015  Yesterday ... NVS Influenza Vaccines Holly Springs manufacturing site located in ... Since 2014, the facility has produced Flucelvax ® ... has the potential for faster start-up and is not ... 2015 CSL Limited acquired the influenza vaccines business of ...
Breaking Medicine Technology:
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... "My friend's ... his fists into his infected cheeks," said an inventor from Platteville, Colo. "I came ... skin problems." , He developed the UNTOUCHABLE to prevent a child from rubbing or ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... of anesthesia and pain management services, today announced its partnership with WPC ... integrates data from disparate systems and organizes the data into an aggregated data ...
(Date:10/13/2015)... ... ... According to an article published October 5th by the American ... weight with a bariatric procedure are much less likely to develop endometrial cancer, which ... from 40 to 50 percent of all endometrial cancer cases are caused by obesity, ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... solutions, announced today their sponsorship of the Microsoft Dynamics AXUG, GPUG and NAVUG ... Summit, GPUG Summit and NAVUG Summit are independent user conferences designed and led ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... provider of IBM software products, introduced a new company, RightSensorâ„¢ LLC, an Internet ... data communications capability. RightSensorâ„¢ provides a fully-managed approach for customers requiring sensor ...
Breaking Medicine News(10 mins):